Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | PRKAG1 | P54619 | 4/20 | 0.44 |
| ▸ | PRKAA1 | Q13131 | 4/20 | 0.44 |
| ▸ | PRKAB1 | Q9Y478 | 4/20 | 0.44 |
| ▸ | PRKAB2 | O43741 | 3/20 | 0.44 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.44 |
| ▸ | PRKAG3 | Q9UGI9 | 3/20 | 0.44 |
| ▸ | PRKAG2 | Q9UGJ0 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10073863 | 0.85 | CYP1A2 (0.50) | SMN1; SMN2PRKAG1PRKAA1PRKAB1PRKAB2 | |
| SCHEMBL13844083 | 0.84 | DYRK1A (0.43) | SMN1; SMN2PRKAG1PRKAA1PRKAB1PRKAB2 | |
| SCHEMBL14387458 | 0.83 | TUBB1 (0.46) | SMN1; SMN2PRKAG1PRKAA1PRKAB1PRKAB2 | |
| SCHEMBL13844093 | 0.80 | PRKAG1 (0.40) | SMN1; SMN2PRKAG1PRKAA1PRKAB1PRKAB2 | |
| SCHEMBL10073860 | 0.80 | PRKAG1 (0.44) | SMN1; SMN2PRKAG1PRKAA1PRKAB1PRKAB2 | |
| SCHEMBL14001681 | 0.79 | TUBB1 (0.52) | SMN1; SMN2PRKAG1PRKAA1PRKAB1PRKAB2 | |
| SCHEMBL13931749 | 0.79 | TUBB1 (0.61) | NPC1RAB9ACASP3SENP8SENP7 | |
| SCHEMBL13844150 | 0.79 | PRKAG1 (0.42) | SMN1; SMN2PRKAG1PRKAA1PRKAB1PRKAB2 | |
| SCHEMBL13794487 | 0.79 | L3MBTL1 (0.47) | SMN1; SMN2PRKAG1PRKAA1PRKAB1PRKAB2 | |
| SCHEMBL13936217 | 0.78 | PRKAG1 (0.39) | SMN1; SMN2PRKAG1PRKAA1PRKAB1PRKAB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562909-B1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK SHARP & DOHME (US) | 2012-06-27 | — | — | EP | disclosed |
| US-7547720-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-7547720-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2009-06-16 | — | — | US | disclosed |
| EP-1663987-B1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO INC (US) | 2009-03-18 | — | — | EP | disclosed |
| US-7410992-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-7410992-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-20070129418-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME LLC | 2007-06-07 | — | — | US | disclosed |
| US-20070129418-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME LLC | 2007-06-07 | — | — | US | disclosed |
| US-7196082-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196082-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-20070010491-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME LLC | 2007-01-11 | — | — | US | disclosed |
| US-20070010491-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME LLC | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010491-A1 | Ophthalmic compositions for treating ocular hypertension | REN, KCNH2, KCNH3 | SMN1; SMN2 1354/4885PRKAG1 2052/4885PRKAA1 1487/4885 |
| US-20070129418-A1 | Ophthalmic compositions for treating ocular hypertension | KCNH2, KCNJ11, KCNN1 | SMN1; SMN2 2010/4885PRKAG1 966/4885PRKAA1 2015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.